FDA approves generic Acticlate Tablets by Lupin
October 04, 2017 | Wednesday | News
They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne
Source: Pixabay
Lupin has recently announced the final approval for its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg from the United States Food and Drug Administration (FDA) to market a generic version of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg.
Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate Tablets, 75 mg and 150 mg.
They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.
Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of approximately USD 263 million in the US (IMS MAT June 2017).
